A substudy analysis was conducted to determine the clinical characteristics associated with symptomatic, laboratory-documented influenza (LDI) among 2215 veterans with chronic obstructive pulmonary disease who participated in Department of Veterans Affairs Cooperative Study 448 and who received trivalent inactivated influenza virus vaccine with or without intranasal live-attenuated, cold-adapted influenza vaccine. Of 585 evaluable first occurrences of acute respiratory illnesses, 94 (16%) were LDI. Respiratory symptoms of cough, sputum production, and dyspnea occurred in 190% of patients with LDI; 68% had documented or subjective fever, and 81% had myalgias. Stepwise logistic regression identified only fever and myalgia as being statistically associated with LDI. During the influenza outbreak period, the positive predictive value of fever and myalgia was 41%. Clinical criteria were poor predictors of LDI in these older, vaccinated patients with chronic lung disease. Additional studies are warranted to define optimal methods for the diagnosis of influenza among older persons with chronic obstructive pulmonary disease.
Influenza is a common respiratory infection that occurs in annual epidemics of varying severity and causes substantial associated morbidity and mortality. Although the epidemic nature of influenza facilitates its recognition within a community, health care providers may have difficulty in distinguishing influenza from other illnesses that occur in an individual patient in winter. "Influenza-like illness" can be caused by a variety of pathogens, including respiratory syncytial virus, other respiratory viruses, and certain bacteria, such as Chlamydia pneumoniae and Mycoplasma pneumoniae [1] [2] [3] .
The timely diagnosis of influenza in an individual patient may be important for treatment or for purposes of infection control [4] [5] [6] [7] [8] [9] .
During the winter, when influenza virus is known to be circulating in the community, acute onset of fever and cough are the best clinical predictors of laboratoryconfirmed influenza among predominantly unvaccinated young and middle-aged adults, with a positive predictive value that ranges from 79% to 87% [10, 11] . For older patients and patients with chronic diseases, however, clinical predictors of influenza illness have not been established. Because influenza vaccine is clearly effective in preventing and ameliorating illness associated with influenza infection, clinical predictors of laboratory-confirmed influenza infection may differ in vaccinated populations and unvaccinated populations [9, [12] [13] [14] [15] .
In Department of Veterans Affairs (VA) Cooperative Study 448, a total of 2215 adults who had chronic obstructive pulmonary disease (COPD) and who were у50 years of age were randomized to receive intra-muscular trivalent inactivated influenza virus vaccine (TIV), either with or without intranasal live-attenuated, cold-adapted influenza vaccine (CAIV-T), in a double-blind manner [16] . Patients were followed prospectively, and acute respiratory illnesses were evaluated. Thus, the study provides a unique opportunity to define the clinical characteristics of influenza among a group of vaccinated older patients with COPD [16] . The purpose of the present study is to compare the clinical characteristics of laboratory-documented influenza (LDI) with those of all other laboratory-assessed acute respiratory illnesses, to identify the clinical predictors of LDI among older, vaccinated individuals.
PATIENTS AND METHODS
VA Cooperative Study 448 was a randomized, double-blind, placebo-controlled trial that compared the efficacy of TIV plus CAIV-T with that of TIV plus placebo at 20 Veterans Affairs sites throughout the United States and Puerto Rico during the 1998-1999 influenza season. The study was approved by the VA Cooperative Studies Program and by the Human Subjects and Research and Development Committees at each of the 20 participating sites. Written and oral informed consent was obtained from all participants. Human experimentation guidelines of the US Department of Health and Human Services and those of the authors' institutions were followed in the conduct of the research.
From 23 November 1998 through 30 April 1999, study personnel conducted active surveillance every 2 weeks by telephone or, if unsuccessful, by mailed postcard, to remind the subjects to contact the study center when they experienced either 3 symptoms of acute respiratory illness or fever (temperature, у37.8ЊC [у100ЊF]) accompanied by 2 symptoms of acute respiratory illness. The symptoms of respiratory illness included new-onset or increased chronic cough, new-onset or increased sputum production, increased dyspnea, chills, headache, myalgias, widespread aches and pains, malaise, sore throat, and nasal congestion. Patients who met the aforementioned criteria for acute respiratory illnesses were clinically evaluated at a study clinic as soon as possible. Severity of illness was assessed using the visual analogue scale and the chronic lung disease severity score.
Nasopharyngeal swab specimens and serum samples were obtained for viral culture and antibody determination, respectively. The subjects were provided with a 7-day diary card on which to record their body temperature and symptoms daily. If the subjects could not come to the clinic, information regarding illness was gathered by telephone. Three to 4 weeks after the onset of acute respiratory illness, the subjects were asked to return so that a serum sample could be obtained for antibody testing. LDI was defined as the sudden onset of respiratory illness plus (1) a nasal swab culture positive for wildtype influenza virus A or B, and/or (2) a 4-fold increase in the titer of antibodies to influenza virus A or B measured in a serum sample obtained 3-4 weeks after the onset of acute respiratory illness, compared with the antibody titer in a serum sample obtained either at the onset of that illness or, if not collected, in a serum sample obtained during a previous visit. A change in the titer of serum antibodies to influenza virus A or B was not used to diagnose wild-type influenza viral infection if acute respiratory illness occurred р28 days after immunization. Nasopharyngeal swab specimens were cultured for influenza virus at the study site or at a reference laboratory. Identification of influenza virus isolates recovered from the study subjects was later confirmed at the central laboratory for the study (St. Louis University, St. Louis, MO). Endpoint titers of serum hemagglutination inhibition antibody were determined at the central laboratory by use of whole virus homologous to the vaccine strains in a standard microtiter assay [16, 17] .
The first episode of acute respiratory illness that occurred 17 days after vaccination, met the study definition of acute respiratory illness, and underwent clinical and laboratory assessment was included in the analysis. The analysis was restricted to the first episode of illness because the methods of analysis that we used assumed independence of observations. Statistical analyses were performed using the SAS software package, version 6.12 (SAS Institute). Descriptive statistics were used for the initial analysis of variables. Univariate logistic regression and analysis were used to identify any association 2 x of treatment group with LDI and clinical symptoms and, also, to compare the prevalence of clinical symptoms of LDI with that of clinical symptoms of illnesses for which influenza test results are negative. We performed multivariate analysis by use of stepwise logistic regression that included all significant independent variables, any significant interaction terms, and any terms involved in a significant interaction to identify symptoms significantly associated with LDI.
RESULTS
A total of 715 total respiratory illnesses and 109 cases of LDI occurred among 2215 study volunteers, for an annual LDI attack rate of 4.9%. Thirty-seven clinic visits for which no clinical information was provided and 93 illnesses that were considered to be recurrent respiratory illnesses in individual patients were excluded from the analysis. Our final analysis included 585 subjects who presented with 585 first episodes of acute respiratory illnesses, of which 94 illnesses were LDI. Of the 94 cases of LDI, 19 (20.2%) were confirmed by culture, and the remainder were confirmed by serologic testing. Of the 88 patients who had one viral type, 59 had type A/H3N2, 5 had type A/ H1N1, and 24 had B virus. Three patients had influenza viruses A and B, and 3 patients had both influenza A subtypes. Treatment group (receipt of either TIV with placebo or TIV with CAIV-T) was not associated with LDI [16] .
The demographic characteristics of the population are listed in table 1. The population was predominantly male and white. The mean age of the subjects was 67.6 years. All met clinical and spirometric criteria for COPD, and 94.2% had у1 other comorbid chronic medical condition. At the time of enrollment in the trial, 8.9% of participants were receiving therapy with orally administered prednisone.
The median time from the onset of illness to clinical assessment was 5.0 days. The clinical characteristics of all illnesses at the time of presentation are listed in table 2. Among patients with LDI, fatigue and/or malaise, dyspnea, cough, and sputum production were common, with each of these characteristics occurring in 190% of study participants. Documented fever was defined as a temperature of у37.8ЊC (у100ЊF) recorded either by study personnel or in a patient diary; subjective fever was defined as a patient's report of feeling feverish. Documented fever was 26% sensitive and 88% specific for LDI. Subjective fever was a more sensitive (65%) and less specific (57%) measure of LDI. The combined fever variable (documented or subjective fever) was 68% sensitive and 54% specific for LDI (table 3) .
Nasal congestion was the only symptom for which the association with LDI depended on the treatment group; it was significantly less frequent in patients with LDI who received TIV with CAIV-T, compared with patients who received TIV with placebo (66.7% vs. 90.4%, respectively;
). Treat-P p .004 ment group did not affect the prevalence of any other symptom or the severity of influenza. However, as a result of the significant association of treatment with nasal congestion, the interaction, presence, or absence of this symptom and the treatment group were included in the multivariate analysis.
In univariate analysis, LDI was statistically associated with documented or subjective fever ( ), dyspnea ( P p .001 P p ), chills (borderline; ), myalgias ( ), wide-.018 P p .061 P p .001 spread aches and/or pains ( ), and fatigue and/or mal-P p .025 aise (
). Severity of LDI and severity of noninfluenza P p .034 respiratory illness were found to be similar on the basis of the visual analogue scale and the chronic lung disease severity score ( and , respectively; data not shown). After step-P p .26 P p .98 wise logistic regression that included each of the significant univariate predictors of LDI, with treatment group, nasal congestion, and the association of treatment group with nasal congestion also included in the model, only documented or subjective fever and myalgia were statistically associated with LDI (table 2). Because LDI accounted for only 16 .1% of acute respiratory illnesses among this immunized population, the positive predictive value of fever, myalgias, or both was low. However, in the absence of myalgias, the probability of not having LDI, or the negative predictive value, was 91.9% (table 3) .
When the analysis was restricted to events that occurred during periods of regional outbreaks of influenza, there were 261 laboratory-assessed illnesses, of which 67 (25.7%) were LDI. The clinical characteristics of LDI and illnesses with negative influenza test results were similar to those listed in table 2. However, because of the increased prevalence of influenza during the outbreak period, positive predictive values for fever and/or myalgias were somewhat higher in the outbreakrestricted analysis, compared with the analysis that included the entire study period (table 3) .
DISCUSSION
Influenza continues to be a common cause of hospitalizations and deaths that occur during winter in the United States, yet the timely diagnosis of influenza infection remains problematic. In this influenza-vaccinated cohort of older patients with COPD, in whom a wide range of respiratory and systemic symptoms was assessed, illness associated with LDI was difficult to distinguish from noninfluenza illness on the basis of clinical criteria. Cough, sputum production, dyspnea, and fatigue were the most common symptoms most frequently associated with LDI, with each being present in 190% of illnesses. These symptoms were also a frequent component of noninfluenza illnesses in patients with underlying lung disease, so their presence was not predictive of etiology. Myalgias were present in 80.9% of patients with LDI, and documented or subjective fever was present in 68.1% of patients with LDI. However, the prevalence of LDI was low in this vaccinated population, even during the a The OR denotes the odds for laboratory-documented influenza in patients with the symptom, compared with the odds for laboratory-documented influenza in patients without the symptom. b Documented fever was defined as a temperature of у37.8؇C (у100؇F) recorded by study personnel or in a patient diary; subjective fever was defined as a patient's report of feeling feverish. c Denotes new or increased symptoms. influenza outbreak. Thus, the positive predictive values of myalgias (34.0%), fever (33.0%), and both fever and myalgias (41.1%) were also low. Our findings are in contrast to those for young, primarily unvaccinated adults, for whom a reliable diagnosis of influenza frequently can be made on the basis of clinical grounds alone [10, 11, 18] . Influenza vaccine can reduce the incidence of febrile episodes in children and adults, including adults with underlying pulmonary disease [19] . Fever was reported by 65% of patients with LDI in our vaccinated cohort and was documented in 26% of patients with LDI. Fever is a well-described feature of influenza in children and in young and middle-aged unvaccinated adults, and it may occur in 70%-90% of such patients [10, 11, [18] [19] [20] [21] [22] [23] [24] . The lower frequency of documented fever in this study may have been the result of the effect of influenza vaccine on attenuating illness, age-related differences in the host response to influenza infection, the use of corticosteroids, or the 5-day delay between the onset of symptoms and presentation at the clinic for evaluation. In a prospective study of influenza in The Netherlands, 34% of vaccinated and unvaccinated persons aged 160 years reported fever as a component of LDI [25] . In a study of patients 165 years of age who were hospitalized with influenza virus A infection, 65% had fever [1] . It is important for physicians to recognize that symptoms of influenza may vary with age, host characteristics, and vaccination status.
The health benefits of influenza vaccine have been clearly established in patients with COPD. In a retrospective cohort study of patients with COPD during 3 influenza seasons, influenza vaccination was associated with a 50% reduction in the number of hospitalizations for pneumonia and influenza and a 70% reduction in the number of deaths due to all causes. In addition, influenza vaccination was associated with fewer outpatient visits for pneumonia, influenza, and all respiratory conditions [26] . Patients' attitudes toward influenza vaccine have an effect on their willingness to be vaccinated [27] . Our data should reassure vaccinated patients with acute, self-limiting respiratory illness that their illness may not be a result of influenza vaccine failure. Even during the influenza outbreak period, LDI accounted for only 25 .7% of all laboratory-assessed illnesses.
Some experts have recommended that all high-risk patients with influenza infection receive antiviral medications [28] . If given within 48 h of the onset of illness, amantadine, rimantadine, and the neuraminidase inhibitors can decrease the duration and severity of influenza, and the neuraminidase inhibitors may also reduce complications [4-7, 18, 28] . Our data indicate that the clinical application of this recommendation will be problematic. Despite enrollment in a clinical trial with reminders given by telephone every 2 weeks, a median of 5.0 days elapsed between the onset of symptoms and the subject's presentation at the facility for clinical evaluation. Similarly, our data indicate that it is difficult to diagnose influenza in a vaccinated population on the basis of clinical grounds alone. Although, in the present study, our laboratory diagnosis of influenza included a test with high sensitivity (serologic testing) and high specificity (viral culture), delay in diagnosis renders both tests impractical for clinical decision-making. Rapid diagnostic tests for influenza may circumvent problems of timing, but the reported sensitivity and specificity of these tests for influenza (45%-90% and 60%-100%, respectively) may be much lower for vaccinated older subjects [29] . PCR may be the most sensitive test, other than serologic testing, for the diagnosis of influenza [30] [31] [32] , but the test has not been standardized and is not available for routine clinical use.
One of the major strengths of this study was the homogeneity of the population with regard to age, sex, and the presence of chronic lung disease. The findings of this study cannot be extrapolated to other populations, however, and they emphasize the importance of similar studies involving populations with different demographic and medical characteristics. In this study, we did not attempt to diagnose pathogens other than influenza virus. It is increasingly recognized that in older, vaccinated populations, other viruses (most notably, respiratory syncytial virus) contribute to influenza-like illness in winter [1] [2] [3] . An additional limitation of this study was that it included only one season of influenza. The effects of influenza in a vaccinated population may vary by year depending on the circulating virus strain and the vaccine match.
In summary, in this cohort of patients with COPD who were vaccinated against influenza, LDI accounted for only 16% of all cases of acute respiratory illness during the winter season. In contrast to studies involving younger individuals, who are not routinely vaccinated, in the present study, clinical criteria were poor predictors of LDI in these vaccinated patients. Because influenza is the only respiratory virus for which oral therapy is available and effective when instituted early in the course of the illness, further studies to define rapid, optimal diagnostic methods for influenza in older persons are warranted. chael P. Habib). The study chairman was G.J.G., and the study biostatistician was T.Z.O.
